In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.75% to 7,120.3 points.
Four ASX shares that are climbing more than most today are listed below. Here's why they are storming higher:
Image source: Getty Images
Ecofibre Ltd (ASX: EOF)
The Ecofibre share price is up 9.5% to 86.5 cents. Investors have been buying the hemp company's shares following the release of an investor update this morning. That update revealed improved momentum in its core United States independent pharmacy business. In April, the Ananda Professional pharmacy segment saw its best month since September 2020.
MoneyMe Ltd (ASX: MME)
The MoneyMe share price has jumped 7.5% to $1.45. This follows the release of a trading update for the month of April. According to the release, the digital credit company delivered record originations of $47 million for the month. This is up 693% over the prior corresponding period. In light of this, the company now expects its gross customer receivables to exceed $300 million in FY 2021. This will be up at least 225% year on year from $134 million in FY 2020.
Nearmap Ltd (ASX: NEA)
The Nearmap share price has surged 14.5% higher to $2.36. This follows the release of an update after the market close on Tuesday. According to the release, trading has remained strong since the end of the first half. As a result, it now expects to deliver annual contract value (ACV) of $128 million to $132 million in FY 2021. This compares to its previous guidance of $120 million to $128 million and will be a 20% to 24% increase on FY 2020's ACV of $106.4 million.
Race Oncology Ltd (ASX: RAC)
The Race Oncology share price has stormed 5.5% higher to $3.24. This follows news that the biotechnology company has raised $5.4 million from institutional and sophisticated investors in an oversubscribed placement. These funds were raised via the issue of 1.8 million new shares at $3.00 per share. Race Oncology intends to use the new capital to help develop its Bisantrene cancer drug.
